FDA Approves Eli Lilly's Once-Weekly Insulin Shot for Type 2 Diabetes

Source Summary

The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval provides patients with an alternative to daily long-acting insulin injections.

Why it matters

The approval expands treatment options for type 2 diabetes patients by reducing injection frequency from daily to weekly, potentially improving medication adherence.

Read the Source

STAT News ↗

NYSE:LLYLive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in ELI LILLY & Co.

Insider activity sentiment

Neutral

BearishNeutralBullish

0 discretionary purchases · 0 discretionary sales

Confidence: Low

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
DirectorSulzberger Gabrielle	Non-informative buy	Common StockCompany grant or award (A)	4.26	—	—	Sep 21, 2026
DirectorLUCIANO JUAN R	Non-informative buy	Common StockCompany grant or award (A)	13.66	—	—	Sep 21, 2026
DirectorFyrwald J Erik	Non-informative buy	Common StockCompany grant or award (A)	8.51	—	—	Sep 21, 2026
DirectorAlvarez Ralph	Non-informative buy	Common StockCompany grant or award (A)	10.66	—	—	Sep 21, 2026
EVP, Global QualitySeymour Melissa	Non-informative sell	Common StockGift or transfer (G)	12	—	—	Sep 9, 2026

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Earnings

Recent reported earnings per share compared with the analyst consensus available from Nasdaq.

Comments

No published comments yet.

Owner	Activity	Change	Shares held	Value (thousands)	Reported
Blackrock, Inc.	Buy	19,273,411 (26.101%)	93,114,973	$110,051,655	6/30/2026
Lilly Endowment Inc	Sell	-1,520,000 (-1.654%)	90,376,978	$106,815,647	6/30/2026
Vanguard Group Inc	Sell	-155,600 (-0.189%)	82,119,557	$97,056,283	12/31/2025
Vanguard Capital Management Llc	Buy	152,945 (0.235%)	65,276,117	$77,149,190	6/30/2026
Pnc Financial Services Group, Inc.	Sell	-6,188 (-0.012%)	51,322,720	$60,657,810	6/30/2026
State Street Corp	Buy	7,748,451 (21.082%)	44,502,808	$52,597,424	6/30/2026
Fmr Llc	Sell	-4,726,101 (-14.238%)	28,466,977	$33,644,835	6/30/2026
Geode Capital Management, Llc	Buy	4,434,551 (19.442%)	27,244,167	$32,199,609	6/30/2026
Vanguard Portfolio Management Llc	Buy	3,988,640 (19.014%)	24,965,667	$29,506,672	6/30/2026
Capital Research Global Investors	Sell	-3,759,507 (-15.262%)	20,873,140	$24,669,755	6/30/2026
Morgan Stanley	Sell	-3,488,932 (-14.81%)	20,069,651	$23,720,120	6/30/2026
Capital World Investors	Sell	-4,551,719 (-22.253%)	15,902,642	$18,795,174	6/30/2026

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Sep 15, 2026	7,519,918	2,204,573	-4.74%	3.41
Aug 31, 2026	7,894,476	2,640,226	+20.26%	2.99
Aug 14, 2026	6,564,742	3,106,628	-28.00%	2.11
Jul 31, 2026	9,117,184	2,316,357	-11.30%	3.94
Jul 15, 2026	10,278,892	2,527,511	+9.90%	4.07
Jun 30, 2026	9,353,153	3,624,842	-3.20%	2.58
Jun 15, 2026	9,662,739	3,211,646	-1.36%	3.01
May 29, 2026	9,795,475	3,307,630	+16.19%	2.96

Fiscal quarter	Reported	EPS	Consensus	Surprise
Jun 2026	Aug 5, 2026	8.38	6.01	+39.43%
Mar 2026	Apr 30, 2026	8.55	7.06	+21.1%
Dec 2025	Feb 4, 2026	7.54	6.99	+7.87%
Sep 2025	Oct 30, 2025	7.02	6.02	+16.61%

Source Summary

Why it matters

Read the Source

NYSE:LLY — Live chart

Insider activity sentiment

Comments

Related stories

FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

FDA Approves New Daily Pill for Advanced Breast Cancer Resistant to Current Treatment

FDA Approves First New Essential Thrombocythemia Drug in 29 Years

Comments

Insider activity sentiment

NYSE:LLYLive chart